Cargando…

Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes

BACKGROUND: Although an increased arterial stiffness has been associated with traditional coronary risk factors, the risk factors and pathology of arterial stiffness remain unclear. In this study, we aimed to identify the plasma metabolites associated with arterial stiffness in patients with type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakami, Naoto, Omori, Kazuo, Taya, Naohiro, Arakawa, Shoya, Takahara, Mitsuyoshi, Matsuoka, Taka-aki, Tsugawa, Hiroshi, Furuno, Masahiro, Bamba, Takeshi, Fukusaki, Eiichiro, Shimomura, Iichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291560/
https://www.ncbi.nlm.nih.gov/pubmed/32527273
http://dx.doi.org/10.1186/s12933-020-01057-w
_version_ 1783545930931240960
author Katakami, Naoto
Omori, Kazuo
Taya, Naohiro
Arakawa, Shoya
Takahara, Mitsuyoshi
Matsuoka, Taka-aki
Tsugawa, Hiroshi
Furuno, Masahiro
Bamba, Takeshi
Fukusaki, Eiichiro
Shimomura, Iichiro
author_facet Katakami, Naoto
Omori, Kazuo
Taya, Naohiro
Arakawa, Shoya
Takahara, Mitsuyoshi
Matsuoka, Taka-aki
Tsugawa, Hiroshi
Furuno, Masahiro
Bamba, Takeshi
Fukusaki, Eiichiro
Shimomura, Iichiro
author_sort Katakami, Naoto
collection PubMed
description BACKGROUND: Although an increased arterial stiffness has been associated with traditional coronary risk factors, the risk factors and pathology of arterial stiffness remain unclear. In this study, we aimed to identify the plasma metabolites associated with arterial stiffness in patients with type 2 diabetes mellitus. METHODS: We used the metabolomic data of 209 patients with type 2 diabetes as the first dataset for screening. To form the second dataset for validation, we enlisted an additional 31 individuals with type 2 diabetes. The non-targeted metabolome analysis of fasting plasma samples using gas chromatography coupled with mass spectrometry and the measurement of brachial-ankle pulse wave velocity (baPWV) were performed. RESULTS: A total of 65 annotated metabolites were detected. In the screening dataset, there were statistically significant associations between the baPWV and plasma levels of indoxyl sulfate (r = 0.226, p = 0.001), mannitol (r = 0.178, p = 0.010), mesoerythritol (r = 0.234, p = 0.001), and pyroglutamic acid (r = 0.182, p = 0.008). Multivariate regression analyses revealed that the plasma levels of mesoerythritol were significantly (β = 0.163, p = 0.025) and that of indoxyl sulfate were marginally (β = 0.124, p = 0.076) associated with baPWV, even after adjusting for traditional coronary risk factors. In the independent validation dataset, there was a statistically significant association between the baPWV and plasma levels of indoxyl sulfate (r = 0.430, p = 0.016). However, significant associations between the baPWV and plasma levels of the other three metabolites were not confirmed. CONCLUSIONS/INTERPRETATION: The plasma levels of indoxyl sulfate were associated with arterial stiffness in Japanese patients with type 2 diabetes. Although the plasma levels of mannitol, mesoerythritol, and pyroglutamic acid were also associated with arterial stiffness, further investigation is needed to verify the results.
format Online
Article
Text
id pubmed-7291560
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72915602020-06-12 Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes Katakami, Naoto Omori, Kazuo Taya, Naohiro Arakawa, Shoya Takahara, Mitsuyoshi Matsuoka, Taka-aki Tsugawa, Hiroshi Furuno, Masahiro Bamba, Takeshi Fukusaki, Eiichiro Shimomura, Iichiro Cardiovasc Diabetol Original Investigation BACKGROUND: Although an increased arterial stiffness has been associated with traditional coronary risk factors, the risk factors and pathology of arterial stiffness remain unclear. In this study, we aimed to identify the plasma metabolites associated with arterial stiffness in patients with type 2 diabetes mellitus. METHODS: We used the metabolomic data of 209 patients with type 2 diabetes as the first dataset for screening. To form the second dataset for validation, we enlisted an additional 31 individuals with type 2 diabetes. The non-targeted metabolome analysis of fasting plasma samples using gas chromatography coupled with mass spectrometry and the measurement of brachial-ankle pulse wave velocity (baPWV) were performed. RESULTS: A total of 65 annotated metabolites were detected. In the screening dataset, there were statistically significant associations between the baPWV and plasma levels of indoxyl sulfate (r = 0.226, p = 0.001), mannitol (r = 0.178, p = 0.010), mesoerythritol (r = 0.234, p = 0.001), and pyroglutamic acid (r = 0.182, p = 0.008). Multivariate regression analyses revealed that the plasma levels of mesoerythritol were significantly (β = 0.163, p = 0.025) and that of indoxyl sulfate were marginally (β = 0.124, p = 0.076) associated with baPWV, even after adjusting for traditional coronary risk factors. In the independent validation dataset, there was a statistically significant association between the baPWV and plasma levels of indoxyl sulfate (r = 0.430, p = 0.016). However, significant associations between the baPWV and plasma levels of the other three metabolites were not confirmed. CONCLUSIONS/INTERPRETATION: The plasma levels of indoxyl sulfate were associated with arterial stiffness in Japanese patients with type 2 diabetes. Although the plasma levels of mannitol, mesoerythritol, and pyroglutamic acid were also associated with arterial stiffness, further investigation is needed to verify the results. BioMed Central 2020-06-11 /pmc/articles/PMC7291560/ /pubmed/32527273 http://dx.doi.org/10.1186/s12933-020-01057-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Katakami, Naoto
Omori, Kazuo
Taya, Naohiro
Arakawa, Shoya
Takahara, Mitsuyoshi
Matsuoka, Taka-aki
Tsugawa, Hiroshi
Furuno, Masahiro
Bamba, Takeshi
Fukusaki, Eiichiro
Shimomura, Iichiro
Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes
title Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes
title_full Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes
title_fullStr Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes
title_full_unstemmed Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes
title_short Plasma metabolites associated with arterial stiffness in patients with type 2 diabetes
title_sort plasma metabolites associated with arterial stiffness in patients with type 2 diabetes
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291560/
https://www.ncbi.nlm.nih.gov/pubmed/32527273
http://dx.doi.org/10.1186/s12933-020-01057-w
work_keys_str_mv AT katakaminaoto plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT omorikazuo plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT tayanaohiro plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT arakawashoya plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT takaharamitsuyoshi plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT matsuokatakaaki plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT tsugawahiroshi plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT furunomasahiro plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT bambatakeshi plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT fukusakieiichiro plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes
AT shimomuraiichiro plasmametabolitesassociatedwitharterialstiffnessinpatientswithtype2diabetes